Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

COVID-19 Turned Oncology Upside Down – How Much Were Cancer Treatment and Early Detection Affected?

COVID-19 Turned Oncology Upside Down – How Much Were Cancer Treatment and Early Detection Affected?

At the start of 2020, the world was suddenly struck by the COVID-19 Pandemic, which arguably turned oncology upside down. This was not unique to oncology, of course, but delays in cancer treatment and disruptions to screening for early detection caused us great concern. Telemedicine (remote healthcare) has become more widespread and, together with coronavirus vaccines, is helping oncology services return to their previous routines, but we cannot yet say we have reached the (new) normal.

Oncologists Report Fewer Patient Visits

Although the number of cancer patients has not fallen, visits to oncology outpatient clinics decreased worldwide during the pandemic. This decrease was particularly pronounced in mid-2020, and numbers have still not returned to their previous levels. This supports concerns about disruptions to cancer treatment and patients presenting to oncology services at more advanced stages.

Murray Aitken and colleagues conducted, among more than 700 oncologists in the United States, United Kingdom, four major European countries and Japan during the pandemic, surveys that showed a substantial decline in oncologists’ reported caseloads compared with pre-COVID-19 levels.

In this survey conducted in April 2020, oncologists reported that visits to oncology clinics had fallen to 49% of prepandemic levels. This rose to 77% in October 2020 but fell again to 74% in February 2021. In other words, Murray Aitken said that, compared with the pre-COVID-19 period, US oncologists experienced a 26% decrease in their caseloads.

However, the US experienced the smallest caseload reduction compared with other countries. According to Murray Aitken, for example, Germany showed, in early 2021 compared with prepandemic levels, a 51% decrease in reported caseloads.

How Did the Pandemic Affect Cancer Care?

COVID-19 also changed the type of care provided to patients. More than three-quarters of US oncologists reported delays in surgery, and 40% reported chemotherapy delays.

The frequency of telemedicine (remote consultations and video calls) rose from less than 10% before the pandemic to 46% in April 2020. Since then, however, remote consultations have declined, most recently accounting for 26% of all oncology consultations in February 2021.

Telemedicine Became a Lifeline for Healthcare

During the pandemic, advances in information technology made it possible to maintain healthcare in oncology and many other fields through telemedicine as a means of providing care. 

According to Murray Aitken, oncologists expect approximately 20% of patient consultations to remain permanently virtual after the COVID-19 pandemic. However, the role these remote consultations will play in providing care, and their impact on outcomes, are still not fully understood. Approximately one-third of oncologists also reported providing patients with more support because of the pandemic.

Alarming Statistics: Missed Screenings and Delayed Diagnoses

Due to COVID-19, the frequency of cancer screening for early detection fell substantially in the US and other countries. In the US in April 2020, mammography, Pap smear, colonoscopy and computed tomography (CT) screenings fell by 87%, 83%, 90% and 53%, respectively, compared with expectations.

Murray Aitken said, "Although these figures have increased since then, it is estimated that there were 20% fewer mammograms, 14% fewer Pap smears, 23% fewer colonoscopies and 11% fewer CT scans over the entire year. In 2020, this means approximately 22 million fewer screening tests for these four cancers than would normally have occurred. In the US alone, in 2020, approximately 68,000 patients may have had a cancer diagnosis delayed or missed.”

Cancer screening worldwide is still below prepandemic levels, and we are concerned that this may have lasting harmful consequences.

Some people who were accustomed to annual mammograms or a colonoscopy every 5 years lost that habit in 2020. Unless we help them return to those habits, there could be a serious setback in the progress made toward early detection.

An Increase in the Proportion of Patients Presenting with Stage 4 Cancer

Data from a US-based panel of 400 oncologists showed, in 2020 (across all major cancers except prostate cancer), a "higher-than-normal" percentage of patients with metastatic disease at presentation.

Everyone is concerned about the increase in patients presenting with metastatic disease and whether this trend will extend into 2021.

Missed screenings during the pandemic and delays in seeking hospital care, even when people have cancer symptoms, are increasing the proportion diagnosed at stage 4 when they present.

The decrease in patients presenting with metastatic prostate cancer may reflect an increasing prevalence of patients with early-stage disease, due to advances in treatment for this cancer type.

Use of Oncology Drugs

Murray Aitken also reported a "sudden drop" in the volume of oncology drugs used worldwide in 2020. The total number of defined daily doses of oncology drugs fell substantially during the pandemic in Europe, the US and Japan.

Aitken said, "Although the volume of drugs used in oncology treatment in the US increased by 6.9% annually in 2018 and 2019, it fell dramatically by 0.1% in 2020. This is a concern, reflecting reduced caseloads, fewer patients being diagnosed and fewer treatments being initiated."

Although in 2020, in both the US and Europe, the use of immunotherapies (checkpoint inhibitors) continued to increase, Aitken and colleagues observed an overall decline in oncology drug use. In 2018, the number of defined daily doses of immuno-oncology drugs increased by approximately 60%. However, this growth rate fell to 36% in 2019 and just 12% in 2020.

Aitken said, "The slowdown in percentage growth for immunotherapies had already begun, but we saw a significant drop in use during the pandemic"

Finally, the substantially greater use of oral cancer medicines in pill/capsule form, also called targeted drugs, appears to have contributed to the decline in intravenously administered chemotherapies. This trend had begun before the pandemic and is expected to continue afterward.

Sources

By Chase Doyle. Impact of COVID-19 on Cancer Treatment and Early Detection: Data-Driven Insights. 23 July 2021. ascopost.com

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

COVID-19 Turned Oncology Upside Down – How Much Were Cancer Treatment and Early Detection Affected?

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy